The complaint filed against the San Diego-based company centers on the unauthorized modification of a statistical analysis plan. According to the court filing, Capricor altered its methodology for evaluating Deramiocel clinical data without securing necessary FDA approval. This omission allegedly rendered the company's subsequent Biologics License Application resubmission and related public disclosures materially misleading to shareholders.
In section Releases
Capricor Therapeutics Faces Class Action Over Deramiocel Disclosures
Investors who held Capricor Therapeutics stock between December 17, 2025, and July 26, 2026, face a looming September 28 deadline to join a class action lawsuit. The litigation targets the biotech firm for alleged securities violations linked to misleading public statements regarding its clinical data analysis for the drug Deramiocel.
DJS Law Group, led by attorney David J. Schwartz, is representing the class. Investors seeking to participate in the litigation or pursue lead plaintiff status are encouraged to contact the firm before the September 28 cutoff. While the firm emphasizes its background in high-stakes corporate governance and securities litigation, participation in this recovery effort does not strictly require an appointment as a lead plaintiff.
Comments (0)
No comments yet. Be the first!